Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU clears Guidant's Multi-Link Frontier bifurcation stent:

This article was originally published in Clinica

Executive Summary

Guidant Multi-Link Frontier stent system treats plaque in coronary arteries at the site of a bifurcation, where one vessel branches from another. The Multi-Link Frontier coronary bifurcation stent is designed to help overcome the problem of blocking blood flow to a side vessel, a concern associated when using traditional stents. It incorporates a novel side-branch portal that allows physicians to preserve access to the side branch. Some 20% of patients treated for coronary artery disease have lesions at bifurcations. The product will be made available in Europe, Australia and New Zealand immediately, and will soon be expanded to countries in Asia and the Middle East.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT058376

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel